FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157003991> ?p ?o ?g. }

• W2157003991 endingPage "2551" @default.
• W2157003991 startingPage "2545" @default.
• W2157003991 abstract "Purpose Despite efforts to intensify chemotherapy, survival for patients with metastatic osteosarcoma remains poor. Overexpression of human epidermal growth factor receptor 2 (HER2) in osteosarcoma has been shown to predict poor therapeutic response and decreased survival. This study tests the safety and feasibility of delivering biologically targeted therapy by combining trastuzumab with standard chemotherapy in patients with metastatic osteosarcoma and HER2 overexpression. Patients and Methods Among 96 evaluable patients with newly diagnosed metastatic osteosarcoma, 41 had tumors that were HER2-positive by immunohistochemistry. All patients received chemotherapy with cisplatin, doxorubicin, methotrexate, ifosfamide, and etoposide. Dexrazoxane was administered with doxorubicin to minimize the risk of cardiotoxicity from treatment with trastuzumab and anthracycline. Only patients with HER2 overexpression received concurrent therapy with trastuzumab given for 34 consecutive weeks. Results The 30-month event-free and overall survival rates for patients with HER2 overexpression treated with chemotherapy and trastuzumab were 32% and 59%, respectively. For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 50%, respectively. There was no clinically significant short-term cardiotoxicity in patients treated with trastuzumab and doxorubicin. Conclusion Despite intensive chemotherapy plus trastuzumab for patients with HER2-positive disease, the outcome for all patients was poor, with no significant difference between the HER2-positive and HER2-negative groups. Although our findings suggest that trastuzumab can be safely delivered in combination with anthracycline-based chemotherapy and dexrazoxane, its therapeutic benefit remains uncertain. Definitive assessment of trastuzumab's potential role in treating osteosarcoma would require a randomized study of patients with HER2-positive disease." @default.
• W2157003991 created "2016-06-24" @default.
• W2157003991 creator A5009993202 @default.
• W2157003991 creator A5010913859 @default.
• W2157003991 creator A5011956202 @default.
• W2157003991 creator A5013088250 @default.
• W2157003991 creator A5017208495 @default.
• W2157003991 creator A5021120123 @default.
• W2157003991 creator A5027865998 @default.
• W2157003991 creator A5032743242 @default.
• W2157003991 creator A5050319286 @default.
• W2157003991 creator A5054775619 @default.
• W2157003991 creator A5067299217 @default.
• W2157003991 creator A5080400582 @default.
• W2157003991 creator A5082899595 @default.
• W2157003991 creator A5085010022 @default.
• W2157003991 creator A5085873078 @default.
• W2157003991 creator A5090325707 @default.
• W2157003991 date "2012-07-10" @default.
• W2157003991 modified "2023-10-18" @default.
• W2157003991 title "Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group" @default.
• W2157003991 cites W1780831116 @default.
• W2157003991 cites W1833330468 @default.
• W2157003991 cites W1856961639 @default.
• W2157003991 cites W1864208984 @default.
• W2157003991 cites W1977566662 @default.
• W2157003991 cites W1992752045 @default.
• W2157003991 cites W1997602199 @default.
• W2157003991 cites W2006508449 @default.
• W2157003991 cites W2011028805 @default.
• W2157003991 cites W2016946966 @default.
• W2157003991 cites W2019267750 @default.
• W2157003991 cites W2023958685 @default.
• W2157003991 cites W2043796364 @default.
• W2157003991 cites W2045471398 @default.
• W2157003991 cites W2050818720 @default.
• W2157003991 cites W2053166784 @default.
• W2157003991 cites W2054740993 @default.
• W2157003991 cites W2072696546 @default.
• W2157003991 cites W2084196088 @default.
• W2157003991 cites W2101253730 @default.
• W2157003991 cites W2123107491 @default.
• W2157003991 cites W2127748864 @default.
• W2157003991 cites W2139537565 @default.
• W2157003991 cites W2140074016 @default.
• W2157003991 cites W2141393790 @default.
• W2157003991 cites W2142136189 @default.
• W2157003991 cites W2146172832 @default.
• W2157003991 cites W2146384083 @default.
• W2157003991 cites W2152647863 @default.
• W2157003991 cites W2154027407 @default.
• W2157003991 cites W2162984113 @default.
• W2157003991 cites W2178975869 @default.
• W2157003991 cites W2318605753 @default.
• W2157003991 cites W2329218644 @default.
• W2157003991 cites W4243636416 @default.
• W2157003991 cites W4246742253 @default.
• W2157003991 doi "https://doi.org/10.1200/jco.2011.37.4546" @default.
• W2157003991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3397787" @default.
• W2157003991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22665540" @default.
• W2157003991 hasPublicationYear "2012" @default.
• W2157003991 type Work @default.
• W2157003991 sameAs 2157003991 @default.
• W2157003991 citedByCount "192" @default.
• W2157003991 countsByYear W21570039912012 @default.
• W2157003991 countsByYear W21570039912013 @default.
• W2157003991 countsByYear W21570039912014 @default.
• W2157003991 countsByYear W21570039912015 @default.
• W2157003991 countsByYear W21570039912016 @default.
• W2157003991 countsByYear W21570039912017 @default.
• W2157003991 countsByYear W21570039912018 @default.
• W2157003991 countsByYear W21570039912019 @default.
• W2157003991 countsByYear W21570039912020 @default.
• W2157003991 countsByYear W21570039912021 @default.
• W2157003991 countsByYear W21570039912022 @default.
• W2157003991 countsByYear W21570039912023 @default.
• W2157003991 crossrefType "journal-article" @default.
• W2157003991 hasAuthorship W2157003991A5009993202 @default.
• W2157003991 hasAuthorship W2157003991A5010913859 @default.
• W2157003991 hasAuthorship W2157003991A5011956202 @default.
• W2157003991 hasAuthorship W2157003991A5013088250 @default.
• W2157003991 hasAuthorship W2157003991A5017208495 @default.
• W2157003991 hasAuthorship W2157003991A5021120123 @default.
• W2157003991 hasAuthorship W2157003991A5027865998 @default.
• W2157003991 hasAuthorship W2157003991A5032743242 @default.
• W2157003991 hasAuthorship W2157003991A5050319286 @default.
• W2157003991 hasAuthorship W2157003991A5054775619 @default.
• W2157003991 hasAuthorship W2157003991A5067299217 @default.
• W2157003991 hasAuthorship W2157003991A5080400582 @default.
• W2157003991 hasAuthorship W2157003991A5082899595 @default.
• W2157003991 hasAuthorship W2157003991A5085010022 @default.
• W2157003991 hasAuthorship W2157003991A5085873078 @default.
• W2157003991 hasAuthorship W2157003991A5090325707 @default.
• W2157003991 hasBestOaLocation W21570039911 @default.
• W2157003991 hasConcept C121608353 @default.
• W2157003991 hasConcept C126322002 @default.
• W2157003991 hasConcept C143998085 @default.
• W2157003991 hasConcept C2776694085 @default.

• next